Loading...
XNAS
AMRN
Market cap342mUSD
Dec 05, Last price  
16.54USD
1D
0.49%
1Q
7.89%
Jan 2017
437.01%
Name

Amarin Corporation PLC

Chart & Performance

D1W1MN
XNAS:AMRN chart
P/E
—
P/S
1.50
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.71%
Rev. gr., 5y
-11.86%
Revenues
229m
-25.51%
500,000500,0007,365,0000000026,351,00054,202,00081,756,000130,084,000181,104,000229,214,000429,755,000614,060,000583,187,000369,193,000306,911,000228,614,000
Net income
-82m
L+39.03%
-18,707,000-26,920,000-38,197,000-20,021,000-59,317,000-249,589,000-69,126,000-179,184,000-166,227,000-56,364,000-115,204,000-86,350,000-67,865,000-116,445,000-22,645,000-18,000,0007,729,000-105,803,000-59,112,000-82,183,000
CFO
-31m
L
-17,306,000-22,909,000-26,279,000-26,392,000-28,112,000-33,870,000-39,439,000-122,303,000-190,336,000-72,309,000-84,748,000-71,815,000-32,837,000-94,703,000-9,366,000-21,746,000-66,537,000-180,092,0006,880,000-31,020,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
URL
https://amarincorp.com/
IPO date
Apr 01, 1993
Employees
365
Domiciled in
IE
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT